Biopharma Dealmaking Quarterly Statistics, Q4 2013
A look at financing, M&A, and alliance activity October–December 2013
Executive Summary
Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.